Recombinant Human Growth Hormone Ameliorates Cognitive Impairment in Stroke Patients.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The researchers aimed to determine the effects of recombinant human growth hormone (rhGH) replacement on cognitive function in subjects with poststroke cognitive impairment using resting-state functional magnetic resonance imaging.

Who Took Part

The study group was 60 patients.

The age groups tagged for this paper are middle-aged adults, both men and women.

All subjects were required to receive the same rehabilitative therapy program.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

The patients were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Some patients received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

The pattern of brain activity was determined by examining the functional connectivity and amplitude of low-frequency fluctuations (ALFF) of blood oxygen level dependent signal.

What Was Measured

PubMed files the paper under topics including Brain, Cognitive Dysfunction, Human Growth Hormone, Magnetic Resonance Imaging, Neuropsychological Tests and Stroke.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 60 patients.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (Journal of computer assisted tomography), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.